- Company
- MSD Korea’s sales 7%↓ due to the transfer of Januvia sales
- by Son, Hyung-Min Apr 15, 2024 06:05am
- The sales of MSD Korea last year declined by 7.3% year-over-year (YoY). The sales of cancer immunotherapy 'Keytruda' have increased significantly, while the sales of COVID-19 treatment 'Lagevrio' have decreased. The company’s external growth appears to have stalled. Moreover, the transfer of local sales rights of a diabetes drug 'Januvia' se
- Company
- Boryung actively pursues co-promotion deals…
- by Kim, Jin-Gu Apr 12, 2024 05:41am
- Boryung proactively seeks opportunities to partner with pharmaceutical and biotechnology companies in South Korea and overseas. Boryung appears to be in full swing after signing a co-distribution agreement with HK inno.N for 'K-CAB' and the four items of 'Kanarb' series at the end of last year. Pharmaceutical industry experts antici
- Company
- ‘Mounjaro may shift the Type 2 diabetes treatment paradigm'
- by Son, Hyung-Min Apr 12, 2024 05:41am
- Mounjaro has shown the most potent effect among incretin-based therapeutic agents. Based on the dramatic effect it showed in reducing blood sugar levels and weight loss in clinical trials, we expect the drug will bring about many changes field of diabetes treatment.” Thomas Forst, Professor of Internal Medicine and Endocrinology at the
- Company
- K-Pharma wins another patent dispute against ‘Entresto’
- by Kim, Jin-Gu Apr 11, 2024 05:45am
- As generic companies win the third trial surrounding the method-of-use patent of Novartis’ ‘Entresto,’ a heart failure treatment, they are one step closer to an early entry of their generic products. Now, the patent hurdle is down to two for early entry of generic versions of Entresto. If generic companies succeed in overcoming the
- Company
- SK’s CMO business posted KRW 812 billion last year…
- by Chon, Seung-Hyun Apr 11, 2024 05:44am
- SK Group's contract manufacturing organization (CMO) business posted a deficit last year. Sales reached nearly KRW 1 trillion, but its growth was sluggish. Investments increased due to the expansion of production facilities at acquired companies, and demand for contract manufacture of COVID-19 drugs from overseas pharmaceutical companies decreas
- Company
- NIP vaccine Vaxneuvance lands in ‘Big 5’ hospitals in KOR
- by Eo, Yun-Ho Apr 11, 2024 05:44am
- The pneumococcal vaccine Vaxneuvance, which can now be received free of charge in Korea, is quickly landing in general hospitals in Korea. According to industry sources, MSD’s vaccine has passed the drug committees (DCs) of the ‘Big 5’ tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Se
- Company
- Mundipharma Korea closes its opioid analgesics business
- by Son, Hyung-Min Apr 9, 2024 05:50am
- Mundipharma Korea is drastically reorganizing its opioid analgesics specialty drug business unit. This is the second time the Korean branch made such large-scale reshuffles since the bankruptcy of its US headquarters, Purdue Pharma in August 2022. The company is known to be searching for a domestic pharmaceutical company to take over the sal
- Company
- Korean and global pharmas in race for lung cancer drugs
- by Son, Hyung-Min Apr 9, 2024 05:50am
- Pharmaceutical and biotechnology companies in South Korea are conducting clinical trials to overcome drug resistance in conventional non-small cell lung cancer (NSCLC) therapy. These companies are developing 4th-generation lung cancer treatments that have proven effective in patients with drug resistance after the use of 1st-to-3rd-generation ta
- Company
- Ilaris reimb passes DREC review, but again with a condition
- by Eo, Yun-Ho Apr 9, 2024 05:50am
- The orphan drug 'Ilaris' has again received a conditional reimbursement decision in Korea. Ilaris (canakinumab), Novartis Korea’s treatment for hereditary periodic fever syndrome, was quickly resubmitted to the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee on the 4th after receiving a conditiona
- Company
- Two new CML drugs were granted reimbursement in one year
- by Eo, Yun-Ho Apr 8, 2024 05:46am
- The chronic myelogenous leukemia (CML) treatment market is starting to show activity again. According to industry sources, treatment options for CML have been expanded with the reimbursement of Novartis Korea's 4th generation CML treatment ‘Scemblix (asciminib) in July last year, and Pfizer Korea’s 2nd generation drug 'Bosulif (bosutini
